eight patients with cavitary disease caused by rmp-resistant m. kansasii were treated with smx-containing regimens that also included high dose inh ( 900 mg ) , emb ( 25 mg/kg ) , and an aminoglycoside ( either streptomycin or amikacin ) .
C0002556
aminoglycoside
C0002499
amikacin